药明康德第三季业绩表现稳健，收入、净利润及订单增长均胜市场预期。期内收入及经调整非国际财务 报告准则净利润分别同比升15%及42%。公司将全年持续经营业务的收入增长指引由13%-17%上调至 17%-18%，并预期全年经调整非国际财务报告准则净利润率将同比进一步提升。该行将药明康德2025至 2027年收入及净利润预测分别上调约2%及4%，以反映第三季业绩超预期及订单持续强劲增长。 智通财经APP获悉，里昂发布研报称，将药明康德H股(02359)目标价由137.1港元升至138.6港元，药明 康德A股(603259.SH)目标价由124.7元上调至126元人民币，均维持"跑赢大市"评级，并将股份列为内地 CRO及CDMO行业的首选。 ...

Core Viewpoint - WuXi AppTec's Q3 performance was robust, with revenue, net profit, and order growth exceeding market expectations [1] Financial Performance - Revenue and adjusted non-IFRS net profit increased by 15% and 42% year-on-year, respectively [1] - The company raised its full-year revenue growth guidance from 13%-17% to 17%-18% [1] - The adjusted non-IFRS net profit margin is expected to further improve year-on-year [1] Future Projections - The revenue and net profit forecasts for WuXi AppTec for 2025 to 2027 were increased by approximately 2% and 4%, respectively, reflecting the strong Q3 performance and continued robust order growth [1] Target Price Adjustments - The target price for WuXi AppTec's H-shares was raised from HKD 137.1 to HKD 138.6, and the A-shares target price was increased from CNY 124.7 to CNY 126 [1] - The rating remains "Outperform" and the shares are considered a top pick in the domestic CRO and CDMO sectors [1]